Gain Therapeutics (NASDAQ: GANX) furnishes investor presentation slides

Rhea-AI Filing Summary

Gain Therapeutics, Inc. filed a current report to state that it has posted an investor presentation on its website. On February 3, 2026, the company furnished a set of business overview slides as Exhibit 99.1. These slides are meant to describe the company’s business and are being provided to the SEC for informational purposes only.

The materials are expressly described as “furnished” rather than “filed,” meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001819411 0001819411 2026-02-03 2026-02-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 3, 2026

Gain Therapeutics, Inc.

(Exact Name of the Registrant as Specified in Charter)

Delaware		001-40237		85-1726310
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4800 Montgomery Lane, Suite 220

Bethesda, Maryland 20814

(Address of principal executive offices) (Zip Code)

(301) 500-1556

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of exchange on which registered
Common Stock, $0.0001 par value	GANX	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD

On February 3, 2026, Gain Therapeutics, Inc. (the “Company”) posted the slides attached hereto as Exhibit 99.1 to this Current Report on Form 8-K on its website to describe its business.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Investor Presentation.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GAIN THERAPEUTICS, INC.
Date: February 3, 2026	By:	/s/ Gene Mack
	Name:	Gene Mack
	Title:	Chief Executive Officer

FAQ

What did Gain Therapeutics (GANX) disclose in its latest 8-K filing?

Gain Therapeutics furnished an investor presentation as Exhibit 99.1, posted on its website, to describe its business. The slides are provided for informational purposes and are not treated as filed under Section 18 of the Exchange Act.

What is the purpose of Gain Therapeutics’ Exhibit 99.1 presentation?

The Exhibit 99.1 presentation is intended to describe Gain Therapeutics’ business to investors and other interested parties. It is shared on the company’s website and furnished to the SEC as supplemental informational material under Item 7.01.

Are Gain Therapeutics’ new slides considered filed with the SEC?

No. The 8-K specifies that the Item 7.01 information, including Exhibit 99.1, is furnished, not filed. This distinction means the slides are not subject to certain Exchange Act Section 18 liabilities or automatically incorporated into other filings.

Does the Gain Therapeutics (GANX) 8-K include financial statements?

The 8-K references Item 9.01 for financial statements and exhibits but only identifies Exhibit 99.1 as slides describing the business. The focus of this report is furnishing that presentation rather than providing detailed financial statements.

Who signed the February 3, 2026 Gain Therapeutics 8-K?

The report was signed on behalf of Gain Therapeutics, Inc. by Gene Mack, its Chief Executive Officer. His signature indicates the company’s authorization of the contents of this current report and the furnishing of the attached exhibit.